Asset

DUSQUETIDE

Soligenix Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02013050phase2completed2013-12-012015-12-01SoligenixA Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
NCT03237325phase3completed2017-12-042020-06-24SoligenixDOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)